TB Bacteria's Trash-Eating Inspires Search for New Drugs
News Jun 11, 2013
They report that bacteria-infecting macrophages – garbage truck-like immune cells – slow their hosts’ trash-processing abilities to snack on trash they pick up. The study, selected as Editor’s Choice in the journal Cellular Microbiology June’s issue, opens a new road in the search for better drugs to fight tuberculosis.
One of the world’s deadliest diseases, tuberculosis has been the No. 1 killer in many regions at different times throughout history, including the United States. It still infects a one-third of the world’s population, according to the Centers for Disease Control, and remains a leading killer of people who are infected with HIV. The bacteria Mycobacterium tuberculosis spread through air to cause the disease in humans and animals, usually attacking the lungs.
Though cases have declined in the United States, other parts of the world are experiencing increased incidence of tuberculosis, and new drug-resistant strains are emerging constantly, raising the stakes in the arms race for treatments.
“We are studying how this microbe deals with its host being an immune cell meant to kill microbes,” said microbiologist David Russell, the William Kaplan Professor of Infection Biology at Cornell’s College of Veterinary Medicine. “We’ve uncovered several ways the microbe changes the macrophage it infects to ensure its survival. Our lab’s drug-discovery branch is now using this new knowledge to identify molecules that could kill M. tuberculosis inside its host after infection.”
Russell’s lab developed a panel of tests that make real-time fluorescent images and quantitative measures of what happens in macrophages – big immune cells that patrol tissues, pick up debris from old or dead cells and sometimes kill microbes they encounter. A macrophage ingests its targets into its phagosome, a stomachlike compartment where it breaks down what has been picked up.
Important things macrophages pick up include low-density lipoproteins (LDLs), which move fatty lipids including cholesterol through the bloodstream. Too many LDLs, also known informally as “bad cholesterol,” can build plaques in arteries that can cause strokes, heart attacks and cardiovascular diseases. Macrophages help prevent plaques by consuming LDLs and breaking down their lipids.
But tuberculosis bacteria cripple infected macrophages’ abilities to process lipids, Russell found. Infected macrophages keep lipids in a way they didn’t before, and the bacteria feed on this fatty refuse while slowing the macrophages’ ability to remove plaque-causing LDLs. Images Russell captured caught the bacteria snacking red-handed, showing lipids moving from the macrophage’s phagosome into the bacteria.
“Seeing this process has helped us design our drug-discovery work to better match what’s happening in human tuberculosis,” said Russell. “Now that we have a better understanding of how these bacteria feed, our lab is looking for compounds that can use their feeding strategy against them to starve them or kill them outright to treat people who have been infected.”
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE